Find an Article

Filter articles

Showing 581 to 590 of 690 results

SPCs: the simplest issue is in doubt

EU28-02-2014Paul England

Recent CJEU decisions on SPCs have brought little clarity to the meaning of ‘product’, and a recent Advocate General opinion in Bayer CropScience AG threatens to muddy the waters even further, says Paul England.

Beyond patent enforcement: the Herceptin phoenix

India28-02-2014Debashish Banerjee and Shukadev Khuraijam

While Western pharmaceutical companies struggle to enforce their IP rights in India, Roche has taken an unorthodox but surprisingly effective stance, as Debashish Banerjee and Shukadev Khuraijam explain.

The Bolar exemption: the question of third parties

EU, Germany28-02-2014Bernd Allekotte

A new referral to the CJEU should shed light on the extent of the so-called Bolar exemption in Europe, says Bernd Allekotte.

Combating cancer: Apexigen and rabbit antibodies


Apexigen uses antibodies derived from rabbits to develop therapies for diseases that are difficult to treat. LSIPR found out how it protects its novel technologies.

Expiring soon: products up for grabs

Germany, Sweden, UK, US19-02-2014

Several of the world’s 10 top-selling drugs lose exclusivity this year. LSIPR takes a look at the products, their major competitors, and their manufacturers’ strategies for keeping a grasp of market share.

A big moment: regulating personal genome services


An individual gene profile provides a window into a person’s medical future, by examining DNA samples, but what are the best ways of regulating this developing technology? LSIPR looks at the challenges and possible solutions.

Burden of proof: US Supreme Court backs licensees

US19-02-2014Matthew Nielsen

The US Supreme Court has again reversed a Federal Circuit decision, this time over burden of proof, says Matthew Nielsen.

SPCs: a call for clarity


The CJEU has delivered its judgment in three SPC cases, in an attempt to address fundamental issues in the SPC Regulation, as well as uncertainties arising from earlier rulings. Although questions have been answered, others have been raised, say David Carling and Michael Pears.

The Glivec case: getting beyond efficacy

India19-02-2014Jitesh Kumar

The Indian Supreme Court has failed to provide the clarity which is craved by practitioners in its latest pronouncement on the controversial Section 3(d), says Jitesh Kumar.

Therapeutic use claims: assessing 'effective' treatment


Common themes, in particular in the context of second medical use claims and dosage regimes, are on the radar of the UK courts, as Jennifer Antcliff and Dennis Waller report.

Showing 581 to 590 of 690 results